Part D Marketing Guidelines Please APhA; Vendor Fees Uncoupled From Risk
Executive Summary
CMS is clarifying that it need not review comparative data that pharmacies use to market Medicare Part D prescription drug plans, so long as the materials stem from an "objective" source